Venture Capital

Insight Partners' new CIO Council is more than a network; it's a strategic nexus where top tech leaders tackle AI and a venture giant refines its next big bets.

As global tech competition fragments, Singapore is forging a direct pipeline for its top innovators to the US market, partnering with elite VCs to turn billions in R&D into global giants.

As Impact Capital Managers brings in heavy-hitters to its board, it’s a clear sign the $80B sector is moving from niche to mainstream. Here’s why.

A 40% drop in early-stage funding reveals a stark reality: Canada's venture capital is consolidating, creating an 'innovation gap' that threatens the nation's future.

Humanoid Global's new partnership aims to unlock Asia's robotics boom. But this bet on the future hinges on a new advisory firm and a non-binding pact.

As the European Venture Fair marks 25 years, its intimate, 'by investors, for investors' model proves more vital than ever for tackling fusion, AI, and the future.

As it turns 50, Menlo Ventures bets a historic $3B on the AI gold rush. Is it the culmination of a visionary legacy or a symptom of market frenzy?

DayMark Wealth Partners and Opto Investments are rewriting the rules, using AI and aligned incentives to bring exclusive private market deals to affluent clients.

Clarevia Ventures' new partner isn't just another investor. She's a top analyst tasked with a critical mission: bridging the gap between science and patient impact.

Middlefield's new Discovery 2026 IPO offers a 100% tax deduction by investing in Canadian gold miners. But is this tax-savvy play worth the inherent risk?

Fintech thrives on data, but a new analysis from the real estate trenches shows emotional connection still drives high-value deals. What can institutional investors learn?

Iris Sun's promotion at 500 Global isn't just a career move. It's a signal of a profound shift in VC, where operational DNA and human agency are the most valuable assets in the AI gold rush.

Kardium’s landmark FDA win and a new wave of innovators signal a biotech boom, cementing British Columbia's status as a global hub for health innovation.

Private equity firm Oakline acquires a major affordable housing manager. Is this the future of community management or a simple play for scale?

A stealth startup just raised $24M from tech's biggest names to solve AI's hardware crisis. Their plan: use AI to design chips, making custom silicon accessible to all.

Beyond amyloid plaques, a new therapy tackles Alzheimer's by reducing inflammation. Longeveron's latest data offers a glimpse into a regenerative future.

As layoffs continue, a new guide reveals the critical mistake leaders make: ignoring the employees who stay. Here's how to rebuild trust and retain talent.

Quoin Pharma is making a bold bet, building a full commercial operation in Japan for its rare disease drug years before a potential launch. Is this the new model?

A public company is offering a volatile mix of OpenAI, Worldcoin, and MrBeast. We deconstruct the high-risk, high-reward strategy behind its unique treasury.

With a fresh $50M, Enhanced Group is selling a future of medically-guided peak performance. But can its controversial Games and peptide platform survive regulatory scrutiny?